癌症免疫疗法，特别是免疫检查点抑制（ICI），已显示出重新激活人体针对肿瘤的免疫反应的潜力。然而，在解决耐药性和提高这些治疗的有效性方面还存在需要克服的挑战。最近的研究强调了铁死亡与免疫细胞内的免疫系统和肿瘤微环境（TME）之间的关系，表明将靶向铁死亡与免疫疗法相结合可以增强抗肿瘤效果。这篇综述探讨了单独使用免疫疗法或与免疫检查点阻断（ICB）疗法、放射疗法和纳米医学协同治疗等其他疗法结合使用免疫疗法来靶向铁死亡的潜力。它还深入研究了不同免疫细胞类型在通过铁死亡促进抗肿瘤免疫反应中的作用。总之，这些发现提供了对专注于铁死亡的协同免疫疗法的全面了解，并为癌症治疗提供了创新策略。© 2024。作者获得 Springer Science Business Media, LLC（Springer Nature 旗下公司）的独家许可。

Immunotherapies for cancer, specifically immune checkpoint inhibition (ICI), have shown potential in reactivating the body's immune response against tumors. However, there are challenges to overcome in addressing drug resistance and improving the effectiveness of these treatments. Recent research has highlighted the relationship between ferroptosis and the immune system within immune cells and the tumor microenvironment (TME), suggesting that combining targeted ferroptosis with immunotherapy could enhance anti-tumor effects. This review explores the potential of using immunotherapy to target ferroptosis either alone or in conjunction with other therapies like immune checkpoint blockade (ICB) therapy, radiotherapy, and nanomedicine synergistic treatments. It also delves into the roles of different immune cell types in promoting anti-tumor immune responses through ferroptosis. Together, these findings provide a comprehensive understanding of synergistic immunotherapy focused on ferroptosis and offer innovative strategies for cancer treatment.© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.